PTO

UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No. First Inventor		PC25604A		
		Masanori Hizue, et al.		
Title	METHOD OF POTENTIAL COMPO	N EFFECTIVE IN TREATMENT OF MECHANICAL ALLODYNIA, SCREENING UND AS SAID PHARMACEUTICAL COMPOSITION, INSPECTION METHOD OF		

	Express Mail Label No. ER190764738US						
APPLICATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application						
See MPEP chapter 600 concerning utility patent application conte							
See MPEP chapter 600 concerning utility patent application conterns. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 40] (preferred arrangement set forth below) Descriptive title of the invention Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Sheets 2 5. Oath or Declaration [Total Pages 3 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed of the prior application, see 37 CFR	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) 11. English Translation Document (if applicable) 12. Information Disclosure Statement (IDS)/PTO-1449 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s)						
1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: Certificate of Express Mail						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No.: Prior application information: Examiner: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.							
19. CORRESP	NDENCE ADDRESS						
Customer Number or Bar Code Label (Insert) Customer (No. or/Attach bar code label (Insert) Customer (No. or/Attach bar code l							
Name David R. Kurlandsky							
Warner-Lambert Company LLC Address 2800 Plymouth Road							
City Ann Arbor	Ann Arbor State Michigan Zip Code 48105						
Country USA							
Name (Print/Type) David R. Kurlandsky Registration No. (Attorney/Agent) 41,505							

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

EXPRESS MAIL NO. ER190764758US DOCKET NO. PC25604A

Approved for use through 04/30/2003. OMB 0651-035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANS	MITTAL	Complete if Known			
FEE IRANS	WILLAL	Application Number			
for FY 2	003	Filing Date			
Effective 01/01/2003. Patent fees are sub		First Named Inventor	Masanori Hizue, et al.		
		Examiner Name			
Applicant claims small entity status. S		Art Unit			
TOTAL AMOUNT OF PAYMENT (\$) 1,286.00		Attorney Docket No.	PC 25604A		

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit card Money Other None	3. ADDITIONAL FEES					
Deposit Account:	Large E	ntity	Small	Entity		
	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Eco Poid
Account Number 23-0455	1051	130	2051		Surcharge - late filing fee or oath	Fee Paid
Deposit Account Warner-Lambert Company LLC	1052	50	2052		Surcharge - late provisional filing fee or cover sheet	
Name	1053	130	1053	130	Non-English specification	
The Commissioner is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1812		1812		For filing a request for ex parte reexamination	
Charge any additional fee(s) during the pendency of this application	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
FEE CALCULATION	1251	110	2251	55	Extension for reply within first month	
1. BASIC FILING FEE	1252	410	2252	205	Extension for reply within second month	ļ
Large Entity Small Entity	1253	930	2253	465	Extension for reply within third month	
Fee Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	1254	1,450	2254	725	Extension for reply within fourth month	
1001 750 2001 375 Utility filing fee	1255	1,970	2255	985	Extension for reply within fifth month	ļ
1002 330 2002 165 Design filing fee \$770.00	1401	320	2401	160	Notice of Appeal	
1003 520 2003 260 Plant filing fee	1402	320	2402	160	Filing a brief in support of an appeal	
1004 750 2004 375 Reissue filing fee	1403	280	2403	140	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$)770.00	1452	110	2452	55	Petition to revive - unavoidable	
	1453	1,300	2453	650	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650	Utility issue fee (or reissue)	
Extra Claims below Fee Paid Total Claims 12 20** - 0 x \$18.00 = 0.00	1502	470	2502	235	Design issue fee	
Independent -20 - A A A A A A A A A A A A A A A A A A	1503	630	2503	315	Plant issue fee	
16.00 Claims 9 -3** = 6 X 586.00 = 516.00	1460	130	1460	130	Petitions to the Commissioner	
0.00	1807	50	1807	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Fee Description	1806	180	1806		Submission of Information Disclosure Stmt	
Code (\$)	8021	40	8021	1 40	Recording each patent assignment per property (times number of properties)	
1202	1809	750	2809	375	Filing a submission after final rejection	
1203 280 2203 140 Multiple dependent claim, if not paid	1810	750	2810	375	(37 CFR 1.129(a)) For each additional invention to be	
1204 84 2204 42 ** Reissue independent claims					examined (37 CFR 1.129(b))	$\vdash \vdash \vdash$
over original patent	1801	750	2801		Request for Continued Examination (RCE)	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 516.00	Other fee (specify)					
**or number previously paid, if greater; For Reissues, see above	*Redu	ced by	Basic f	Filing F	ee Paid SUBTOTAL (3) (\$) \$0.0	00

SUBMITTED BY							(Complete	(if applicable)
Name (Print/Type)	Ī	avid R. Ku	rlandsky		Registration No. (Attorney/Agent)	41,505	Telephone	
Signature	\Box	5		<u> </u>			Date	330 2000

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MA Applicant(s): Masanori Hizue,	Docket No. PC25604A					
Serial No.	Serial No. Filing Date Examiner					
METHOD OF POTENTIAL (POSITION EFFECTIVE IN TREAT COMPOUND AS SAID PHARMA A, AND TREATMENT METHOD	CEUTICAL COMPOSITION, IN:	SPECTION METHOD OF			
I hereby certify that this	Utility Patent Application Under 3	7 CFR 1.53(b) (Identify type of correspondence)				
•	nited States Postal Service "Expanderessed to: Commissioner for					
		(Typed or Printed Name of Person ER190	A. Zerby Person Mailing Correspondence) Mailing Correspondence 764758US Mailing Label Number)			
	Note: Each paper must have	its own certificate of mailing				